Roche Holding AG (TSX:ROG) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:ROG Roche Holding AG TSX:ROG
55 GF Score
Price C$26.45
GF Value C$20.02
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Roche Holding AG Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

TSX:ROG
55GF Score
Roche Holding AG TSX:ROG
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roche Holding AG (TSX:ROG) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of C$26.45 is trading 32.1% above its estimated GF Value™ of C$20.02. GuruFocus considers Roche Holding AG to be Significantly Overvalued.

Key valuation signals for TSX:ROG:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: C$20.02 vs. price of C$26.45 (32.1% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the TSX:ROG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
55GF Score

Get the complete analysis for TSX:ROG

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$26.45
Price
C$20.02
GF Value